Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1052 clinical trials
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC. The study will be performed in two stages. During Stage 1, two cohorts will be enrolled in parallel in this study: …

erbb2
breast cancer
measurable disease
atezolizumab
combinations
  • 309 views
  • 27 Jul, 2022
  • 28 locations
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA …

PIK3CA
PTEN
metastasis
breast cancer
measurable disease
  • 73 views
  • 08 Aug, 2022
  • 188 locations
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).

breast cancer
measurable disease
atezolizumab
cancer
taxane
  • 296 views
  • 12 Jul, 2022
  • 74 locations
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physician´s choice (TPC, defined as capecitabine or platinum-based chemotherapy …

erbb2
endocrine therapy
BRCA1
HER2
anthracyclines
  • 10 views
  • 28 Apr, 2022
  • 69 locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

mammogram
measurable disease
paclitaxel
breast cancer
formalin-fixed paraffin-embedded
  • 1671 views
  • 09 Aug, 2022
  • 27 locations
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib Carelizumab Plus Nab-paclitaxel and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

This randomized, open-label phase 3 study will evaluate the safety and efficacy of Carelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) in combination with Nab-paclitaxel and Apatinib, carelizumab plus nab-paclitaxel, and Nab-paclitaxel in Patients with Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer. Participants will be randomized in a …

erbb2
breast cancer
measurable disease
locally advanced breast cancer
cancer
  • 11 views
  • 24 Jan, 2021
  • 1 location
Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

Background People can feel different levels of pain. This may depend on social, cultural, and biological factors. These factors can also influence how people respond to each other, and how they judge other people s experiences. Researchers want to learn more about these relationships. Objective To study if social and …

pain assessment
Accepts healthy volunteers
heat
  • 138 views
  • 28 Jul, 2022
  • 1 location
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Primary aim: Pathological complete response rate after preoperative chemotherapy is the primary end-point of the study, which will be evaluated by comparing the effects of neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine on Pathological Complete Response (pCR).

erbb2
immunohistochemistry
adenocarcinoma of the breast
progesterone
BRCA1
  • 5 views
  • 23 Mar, 2022
  • 11 locations
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (ATRACTIB)

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate to evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer (mTNBC)

erbb2
immunohistochemistry
measurable disease
avastin
progesterone
  • 0 views
  • 19 Jun, 2022
  • 23 locations
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis

The primary objective is to determine whether Leukotriene A4 hydrolase (LTA4H) genotype, defined at randomisation, determines dexamethasone's clinical effectiveness when added to the first 6-8 weeks of anti-tuberculosis treatment of TBM. The investigators will conduct a LTA4H genotype stratified, parallel group, randomised, double blind, placebo-controlled multi-centre Phase III non-inferiority trial …

rifampin
tuberculosis treatment
corticosteroids
isoniazid
tb chemotherapy
  • 53 views
  • 28 Apr, 2022
  • 1 location